Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.

Autor: Weil CR; Department of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT, USA., Qian Y; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA., Von Eyben R; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA., Daadi SE; Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA., Corbelli KS; Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA., Rosenberg SA; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.; Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA., Advani RH; Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA., Hoppe RT; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2020 Oct; Vol. 61 (10), pp. 2428-2434. Date of Electronic Publication: 2020 May 30.
DOI: 10.1080/10428194.2020.1768385
Abstrakt: Management of stage I-II unfavorable risk Hodgkin lymphoma (HL) strives to reduce toxicity while maintaining tumor control. Compared to ABVD or BEACOPP, Stanford V chemotherapy contains less doxorubicin and bleomycin. We report long-term outcomes of patients with stage I-II classic HL with European risk factors treated with Stanford V combined modality therapy (CMT). From our institutional cancer registry, we identified 168 patients with ≥1 European risk factor treated with 8-12 weeks of Stanford V CMT and consolidative radiotherapy between 1990 and 2016. Outcomes were analyzed after classification by EORTC and GHSG unfavorable criteria. With median follow-up of 8.4 years, 10-year overall survival and progression-free survival for the entire cohort were 95% and 88%, respectively. Thirteen of 18 relapses were salvaged successfully. There were no cases of MDS or AML after primary therapy. Long-term outcomes of stage I-II unfavorable risk HL treated with Stanford V CMT are comparable to ABVD or BEACOPP regimens.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje